EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

Preventing Cardiomyopathy in Duchenne Muscular Dystrophy: Long‐Term Follow‐Up of Patients in the Randomised, Placebo‐Controlled Drug‐Trial of Perindopril and Bisoprolol

John P Bourke iD, Andrew Bryant, Gregory Landon, Alexis Burn, Stefan Spinty, Ros Quinlivan, Zoya Alhaswani, Thomas Chadwick, Francesco Muntoni, Michela Guglieri, DMD Heart Study Group

European Journal of Neurology · 2025

DOI: 10.1111/ene.70097 ↗

At a glance

Randomisierte kontrollierte Studie in European Journal of Neurology, 2025. Written by John P Bourke and 10 co-authors. Institution: Department of Cardiology, Freeman Hospital, Newcastle Hospitals Foundation Trust & John Walton Muscular Dystrophy Research Centre, Newcastle Universi…. Major MEDLINE topics: Bisoprolol, Perindopril, Muscular Dystrophy, Duchenne, Cardiomyopathies. Cited 5 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Duchenne UK, Duchenne Research Fund.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

It is uncertain whether using cardiac drugs prophylactically in combinations for DMD is better than ACE‐inhibitor alone. Our previous study showed no differences in left ventricular function between perindopril‐bisoprolol and matched placebo after 36 months.

Methods

This study aimed to determine whether heart measures diverged after 60‐month total follow‐up. All participants had commenced open‐label perindopril and bisoprolol when the original study ended. All were reconsented for access to heart measures, undertaken as part of their clinical care. The primary outcome was the change in echo‐measured ventricular ejection fraction from baseline according to original randomization.

Results

Of 75 participants reported originally, 65 (aged 16 ± 2.5 years) were re‐recruited and had data for analysis. Adjusted primary outcomes included 44 participants (original arms: ‘active’ 21; ‘placebo’ 23), 48 for secondary outcomes, and 65 for ‘headcount’ analysis of those with ventricular dysfunction. Absolute LVEF% values reduced in both groups (‘active’: 62.5% ± 5.6% to 53.8% ± 4.0%; ‘placebo’: 60.6% ± 4.9% to 50.4% ± 8.5%). Despite trends favoring earlier introduction of therapy, change from baseline was similar between groups (adjusted mean difference: ‐7.7 (95% CI ‐16.4 to1.0%)). However, more in the ‘placebo’ arm had died, had reduced LVEF%, and were taking additional heart medications.

Conclusion

While some patients may have benefited from ‘early’ (active) as opposed to ‘delayed’ (placebo) initiation of perindopril and bisoprolol, group‐mean ventricular function did not differ between study arms after 60 months. Small numbers, absence of a control group, insensitivity of echo‐ejection fraction, and additional drug use probably prevented divergence between groups.

Subjects

MeSH terms (MEDLINE)

BisoprololPerindoprilMuscular Dystrophy, DuchenneCardiomyopathiesAngiotensin-Converting Enzyme InhibitorsHumansMaleFollow-Up StudiesAdolescentAdrenergic beta-1 Receptor AntagonistsYoung AdultTreatment OutcomeAdult

Author keywords

ACE‐inhibitorDMDbeta‐blockercardiomyopathy preventionheart medicationsprophylaxis

Substances

BisoprololPerindoprilAngiotensin-Converting Enzyme InhibitorsAdrenergic beta-1 Receptor Antagonists

Authors and institutions

  • Department of Cardiology, Freeman Hospital, Newcastle Hospitals Foundation Trust & John Walton Muscular Dystrophy Research Centre, Newcastle University, and Newcastle Hospitals Foundation Trust, Newcastle upon Tyne, UK.
  • John Walton Muscular Dystrophy Research Centre, Newcastle University, and Newcastle Hospitals Foundation Trust, Newcastle upon Tyne, UK.
  • Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
  • NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, University College London, & Great Ormond Street Hospital Trust, London, UK.
  • Newcastle Joint Research Office, Newcastle University/The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Department of Paediatric Neurology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

ORCID profiles: John P Bourke

Funding

  • Duchenne UK
  • Duchenne Research Fund

Cite

APA

Bourke, J. P., Bryant, A., Landon, G., Burn, A., Spinty, S., Quinlivan, R., Alhaswani, Z., Chadwick, T., Muntoni, F., Guglieri, M., & DMD Heart Study Group (2025). Preventing Cardiomyopathy in Duchenne Muscular Dystrophy: Long‐Term Follow‐Up of Patients in the Randomised, Placebo‐Controlled Drug‐Trial of Perindopril and Bisoprolol. European Journal of Neurology. https://doi.org/10.1111/ene.70097

Vancouver

Bourke JP, Bryant A, Landon G, Burn A, Spinty S, Quinlivan R, et al. Preventing Cardiomyopathy in Duchenne Muscular Dystrophy: Long‐Term Follow‐Up of Patients in the Randomised, Placebo‐Controlled Drug‐Trial of Perindopril and Bisoprolol. European Journal of Neurology. 2025. doi:10.1111/ene.70097

BibTeX
@article{Bourke2025,
  author = {Bourke, John P and Bryant, Andrew and Landon, Gregory and Burn, Alexis and Spinty, Stefan and Quinlivan, Ros and Alhaswani, Zoya and Chadwick, Thomas and Muntoni, Francesco and Guglieri, Michela and DMD Heart Study Group, DMD Heart Study Group},
  title = {Preventing Cardiomyopathy in Duchenne Muscular Dystrophy: Long‐Term Follow‐Up of Patients in the Randomised, Placebo‐Controlled Drug‐Trial of Perindopril and Bisoprolol},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70097}
}
Start for free →